AI Article Synopsis
- Pregnancy in women with multiple sclerosis does not lead to long-term increases in disability, but there is a higher chance of relapses after childbirth.
- The safety of therapies used during pregnancy, especially immunomodulating drugs, is still unclear due to limited research.
- It is recommended that certain medications like glatiramer acetate, mitoxantrone, and interferon-beta be stopped before pregnancy, while glucocorticoids can be used for acute relapses.
Article Abstract
In women with multiple sclerosis, pregnancy does not have a long-term adverse effect on lifetime disability; however, there is an increased risk of relapses during the postpartum. Therapies taken during pregnancy may have adverse effects on pregnancy outcome. The small number of pregnancies included in most studies, particularly those evaluating the risks related to the administration of immunomodulating drugs, do not allow firm conclusions to be drawn with regards to their safety. Therefore, until more information regarding safety is available, glatiramer acetate, mitoxantrone and interferon-beta should be discontinued before an anticipated pregnancy. By contrast, glucocorticoids can be used to treat acute relapses during pregnancy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737175.6.12.1823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!